Biogen julkaisee uutta tietoa SPINRAZA®-lääkkeestä (nusinerseeni) spinaalisen lihasatrofian (SMA) hoidossa

• NURTURE on avoin tutkimus, johon otettiin mukaan enintään 6 viikon ikäisiä vielä oireettomia geneettisen SMA-diagnoosin saaneita vauvoja. Iän mediaani ensimmäisen annoksen ajankohtana oli 22 vuorokautta.
• NURTURE-tutkimuksen uudet tulokset osoittavat, että nusinerseenilla hoidetut oireettomat  lapset  saavuttivat motorisissa toiminnoissa kehitystasoja, jotka ovat ennennäkemättömiä SMA-taudin luonnollisessa etenemisessä: lapsista 100 prosenttia  kykenee istumaan ilman tukea ja 88 prosenttia kykenee kävelemään itsenäisesti.
• Tulokset vahvistavat nusinerseenin turvallisuutta ja pitkän aikavälin tehoa sekä osoittavat, että hoito johtaa jatkuvaan paranemiseen motorisissa toiminnoissa, kun hoito aloitetaan jo ennen oireiden ilmaantumista.
• Nusinerseeni on ainoa SMA:han hyväksytty hoito, jolla on näyttöä laajasta kirjosta potilaita sekä kokemusta yli 7500 potilaan hoidosta.

Cambridgen Yliopisto. – 1.7.2019: Biogen (Nasdaq: BIIB) julkaisi eilen NURTURE-tutkimuksen uusia tuloksia. NURTURE on pitkäkestoisin SMA-tutkimus oireettomilla vauvoilla (n=25). Tutkimustulokset osoittivat (45,1 kuukauden analyysin kohdalla) hoidon tehokkuuden ja turvallisuuden sellaisilla potilailla, joita hoidettiin nusinerseenilla ennen oireiden ilmaantumista verrattuna sairauden tavalliseen etenemiseen. Nämä uudet tutkimustulokset osoittivat myös, että nusinerseenilla hoidetuilla potilailla istuminen ja käveleminen itsenäisesti paranivat. Lisäksi suurin osa potilaista saavutti motoristen toimintojen kehitystasoja samassa aikataulussa kuin lapset, joilla ei ole SMA:ta.

Nämä tulokset julkistettiin Cure SMA:n vuosittaisessa SMA-konferenssissa Anaheimissa, Kaliforniassa (28.6.-1.7.2019) ja Euroopan neurologian akatemian (EAN) viidennessä kongressissa Oslossa, Norjassa (29.6.-2.7.2019).

TIETOA SPINAALISESTA LIHASATROFIASTA (SMA)

SMA (Spinal Muscular Atrophy) on spinaalinen lihasatrofia. Se on harvinainen geneettinen sairaus, joka hoitamattomana aiheuttaa vaikeaa etenevää liikuntakyvyttömyyttä ja usein lyhentää elämän pituutta merkittävästi.

Spinaalista lihasatrofiaa aiheuttaa SMN1 (survival motor neuron 1) -geenin puutteet tai mutaatio. Tämä geeni vastaa SMN-proteiinin tuottamisesta, joka ylläpitää motoristen neuronien normaalia toimintaa. Spinaalista lihasatrofiaa sairastavilla potilailla on SMN1-geenin puutteita tai mutaatioita, mikä johtaa SMN-proteiinin tuotannon vähenemiseen. Spinaalinen lihasatrofia (SMA) on harvinainen, geneettinen, neuromuskulaarinen sairaus, jota esiintyy aikuisilla, lapsilla ja imeväisillä.

SMN-proteiini on välttämätön motoristen toimintojen ylläpitämiseksi. SMN-proteiinin puute aiheuttaa vakavaa ja etenevää lihasten surkastumista ja heikkoutta. SMA:ta sairastavat tarvitsevat merkittävästi terveydenhuollon tukea.

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

• New results from the NURTURE study demonstrate that pre-symptomatic infants treated with nusinersen are achieving motor milestones that are unprecedented in the natural history of the disease, including 100 percent of children sitting without support and 88 percent walking independently
• Results add to the body of evidence supporting the safety and long-term efficacy of nusinersen and demonstrate that treatment results in continuous improvement from the start of treatment in attaining motor milestones
• Nusinersen is the only treatment approved for infants, children and adults with evidence across a broad range of patients and real-world experience treating more than 7,500 patients

Cambridge, Mass. – July 1, 2019 – Biogen (Nasdaq: BIIB) today announced new results from the NURTURE study, adding data to the longest study of spinal muscular atrophy (SMA) in pre-symptomatic infants (n=25). These data reported, after up to 45.1 months of analysis, continue to demonstrate efficacy and safety in patients treated pre-symptomatically with nusinersen in comparison to the natural history of this disease. These new data also showed that patients treated with nusinersen had continuous improvement in sitting and walking independently, with the overwhelming majority of patients achieving motor milestones in a normal timeframe.  

These data are being presented at the Cure SMA Annual SMA Conference in Anaheim, CA (June 28-July 1, 2019) and the 5th Congress of the European Academy of Neurology (EAN) in Oslo, Norway (June 29-July 2, 2019).

Results from NURTURE, an ongoing, Phase 2, open-label study of 25 pre-symptomatic patients with SMA (most likely to develop SMA Type 1 or 2) who received their first dose of SPINRAZA before six weeks old, demonstrated unparalleled results in comparison to the natural history of SMA. As of March 2019:  

•  100 percent were alive without a need for permanent ventilation.
•  The median age of the study participants was nearly three years old. The majority of untreated patients with SMA Type 1 never reach their second birthday without permanent ventilation.
•  100 percent of the infants were sitting independently, in comparison to the natural history of this disease where no patients with SMA Type 1 would be able to do so and patients with SMA Type 2 would need assistance.
•  88 percent of the infants were walking independently with many of them doing so in the normal timeframe for a toddler. In the natural history of SMA, patients with SMA Type 1 or Type 2 are never able to walk independently.
•  Patients were approaching the maximum mean score of 64 on the CHOP INTEND measure of motor function – 63.4 for patients with 3 SMN 2 copies (n=10) and 62.1 for those with 2 SMN 2 copies (n=15), demonstrating the impact of early SPINRAZA treatment.
•  SPINRAZA demonstrated efficacy up to nearly 4 years, with participants continuing to make progress and showing no signs of loss of motor function.
•  SPINRAZA was well-tolerated with no new safety concerns identified after up to nearly 4 years of treatment.

Additional presentations at the two meetings highlight results from the ongoing open-label SHINE extension study of children with infantile and later-onset SMA as well the CS2/CS12 analysis of older patients. Biogen also continues to explore the scientific value of phosphorylated neurofilament heavy chain (pNF-H) and will present new data on the ongoing evaluation of its potential as a biomarker in SMA.

About SPINRAZA® (nusinersen)1-4 

Nusinersen is the first therapy approved to treat infants, children and adults with spinal muscular atrophy (SMA) and is available in more than 40 countries. As of March 31, 2019, more than 7,500 individuals have been treated with SPINRAZA for up to six years, based on patients across the post-marketing setting, Expanded Access Program (EAP) and clinical trial participants. SPINRAZA is the only SMA treatment to combine unsurpassed real-world experience and the highest level of clinical evidence across a broad spectrum of patient populations.

SMA is a rare, genetic, neuromuscular disease that is characterized by a loss of motor neurons in the spinal cord and lower brain stem, resulting in severe, progressive muscle atrophy and weakness. Approximately one in 10,000 live births have a diagnosis of SMA and people of all ages are impacted by the disease. It is a leading genetic cause of infant mortality.

Nusinersen, a foundation of care in SMA, is an antisense oligonucleotide (ASO) designed to target a root cause of SMA by increasing the amount of full-length survival motor neuron (SMN) protein, which is critical to maintaining motor neurons. It is administered by intrathecal injection into the fluid surrounding the spinal cord where motor neurons reside to deliver the treatment where the disease starts.

Nusinersen currently maintains the largest clinical data set in SMA based on data from over 300 patients across a broad range of SMA populations demonstrating a favorable benefit:risk profile. Nusinersen was evaluated in two randomized, double-blind, sham-controlled studies (ENDEAR and CHERISH) in infantile and later-onset SMA patients and supported by open label studies in pre-symptomatic infants (NURTURE) and individuals who were treated into adulthood with later-onset SMA (CS2/CS12). The most common adverse events observed were headache, vomiting and back pain. Serious infections of hydrocephalus and meningitis have been observed in the post-marketing setting. Renal toxicity and coagulation abnormalities, including acute severe low platelet counts, have been observed after administration of some ASOs. Laboratory tests can monitor for these signs.

Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), a leader in antisense therapeutics. Biogen and Ionis conducted an innovative clinical development program that moved nusinersen from its first dose in humans in 2011 to its first regulatory approval in five years.

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Biogen Safe Harbor

This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the potential benefits, safety and efficacy of SPINRAZA; the results of certain real-world data; and the identification and treatment of SMA. These statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis; failure to obtain regulatory approvals in other jurisdictions; risks of unexpected costs or delays; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this news release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Reference:

1. Finkel, Richard S., et al. “Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.” New England Journal of Medicine, vol. 377, no. 18, 2017, pp. 1723–1732., doi:10.1056/nejmoa1702752.
2. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell.1995;80(1):155-165.
3. Mercuri, Eugenio, et al. “Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.” New England Journal of Medicine, vol. 378, no. 7, 2018, pp. 625–635., doi:10.1056/nejmoa1710504.

Basil T. Darras, et al. “Nusinersen in later-onset spinal muscular atrophy.” Neurology, May 2019, 92 (21) e2492-e2506; DOI:10.1212/WNL.0000000000007527

MEDIA CONTACT:

David Caouette
+ 617 679 4945
public.affairs@biogen.com

INVESTOR CONTACT:

Joe Mara
+1 781 464 2442
IR@biogen.com  

Avainsanat: